¡¾²Î¿¼ÎÄÏס¿
  1 Lang GE, H¢|ndel A. Results of laser coagulations of branch retinal vein occlusions. Klin Monatsbl Augenheilkd 1993;203(3):180ª²188

¡¡¡¡2 Esrick E, Subramanian ML, Heier JS, Devaiah AK, Topping TM, Frederick AR, Morley MG. Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 2005;139£¨4£©:653ª²657

¡¡¡¡3 Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treament of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141£¨5£©:876ª²883

¡¡¡¡4 Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treament of persistent macular edema in branch retinal vein occlusion. Eye 2006;20(1):13ª²17

¡¡¡¡5 Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal tramcinolone in central retinal vein occlusion. Am J Ophthomol2004;137£¨4£©:758ª²760

¡¡¡¡6 Ceki¢“ O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005;139£¨6£©:993ª²998

¡¡¡¡7 Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an antiª²VEGF antibody for treating cancer. Nat Rev Drug Discov2004; 3£¨5£©:391ª² 400

¡¡¡¡8 Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, V¢‰lker M, Holz FG, Bartzª²Schmidt KU. Bevacizumab for treament of macular edema secondary to retinal vein occlusion. Ophthalmologe 2006;103£¨6£©:471ª² 475

¡¡¡¡9 Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a shortª²term study. Retinal2006;26£¨3£©:279ª²284

¡¡¡¡10 Rosenfeld PJ, Fung AE, Pulianfito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging2005;36£¨4£©:336ª²339

¡¡¡¡11 Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LE, King GL. Vascular endothelial growth factorª²induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective betaª²isoform inhibitir. Diabetes1997;46£¨9£©:1473ª²1480

¡¡¡¡12 Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA, Schoenfeld CL, Peng B, Chan CC, LaRochelle W, Green WR, Campochiaro PA. Upregulation of vascular endotheial growth factor in ischemic and nonª²ischemic human and experimental retinal disease. Histol Histopathol1997;12£¨1£©:99ª²109

¡¡¡¡13 Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor(VPF) that promites accumulation of ascites fluid. Science1983;219(4587);983ª²985

¡¡¡¡14 Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999;274(33):23463ª²23467

¡¡¡¡15 Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695ª²1705.elª²15

ÉÏÒ»Ò³  [1] [2] [3] [4]